Evidence map›Paper›PMID 42045845›Full record

ArticleBMC gastroenterology2026

Early infliximab rescue therapy is associated with reduced length of stay in patients with acute severe ulcerative colitis.

Mustafa Mohamedrashed, Saiumaeswar Yogakanthi, Ryan Bartlett, Melissa Chew, Leya Nedumannil, Ziheng Calvin Xu, Ayushi Chauhan, Sarah Lucas, Diana Lewis, Robert D Little and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Managing Acute Severe Ulcerative Colitis in 2025 and Beyond.Current gastroenterology reports · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mustafa MohamedrashedDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Saiumaeswar YogakanthiDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Ryan BartlettDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Melissa ChewDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Leya NedumannilDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Ziheng Calvin XuDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Ayushi ChauhanDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Sarah LucasDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Diana LewisDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Robert D LittleDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Soleiman KashkooliDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia.
Mayur GargDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, VIC, 3076, Australia. mayur.garg@unimelb.edu.au.ORCID http://orcid.org/0000-0002-9149-3589

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPatients with acute severe ulcerative colitis (ASUC) inadequately responding to intravenous steroids commonly require rescue therapy, most commonly with infliximab or cyclosporine, traditionally administered on day 3 of admission based on Modified Oxford Criteria. This study aimed to evaluate the impact of early (≤ 72 hours) versus standard (> 72 hours) infliximab administration on different clinical outcomes.

methodsA retrospective medical records review of patients admitted with ASUC who were administered infliximab rescue therapy due to inadequate steroid response was performed. Patients were divided into 2 groups: early infliximab therapy (≤ 72 hours of admission) and standard infliximab therapy (> 72 hours of admission). Outcomes assessed included length of stay, 12-month readmission and colectomy rates, and infective complications.

results84 patients (31 [37%] female, median age 34 [range 29-48.5] years) were included. 31 (37%) received early (median 52 [IQR 45–56] hours) and 53 (63%) had standard (median 105 [IQR 94–149] hours) infliximab therapy, with no significant demographic differences. Median length of stay was shorter in the early vs. standard group at 6 vs. 7 days (p = 0.048). No significant difference was seen in requirement for colectomy at index admission or at 12-months follow up (p > 0.99). Similarly, there was no significant difference in readmission rates at 6- (33.3% vs. 30%, p = 0.76) or 12-months (40% vs. 33.3% p = 0.64). There was no difference in rate of infective complications in the first 30 days.

conclusionEarly infliximab therapy was associated with shorter hospitalisation, with no difference in rates of colectomy, re-admission or infective complications.

Indexed as

Colitis, UlcerativeGastrointestinal AgentsInfliximabLength of StayAcute DiseaseAdultColectomyFemaleHumansMaleMiddle AgedPatient ReadmissionRetrospective StudiesSeverity of Illness IndexTime FactorsTreatment OutcomeGastrointestinal AgentsInfliximabAcute Severe Ulcerative ColitisColectomyInfliximab

Identifiers

PMID42045845
PMCPMC13262430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.